Interestingly, IgE may reprogram monocytes and macrophages toward cytotoxic functions, 7,41 and the first therapeutic application of tumor-specific IgE antibody MOv18 in ovarian cancer patients is presently ongoing in a registered clinical trial (NCT02546921). The gene discussed is IGHE; the disease is ovarian carcinoma.